Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Bernhard Hemmer(Munich Cluster for Systems Neurology), Fred Lublin(Icahn School of Medicine at Mount Sinai), Hideki Garren(Io Therapeutics (United States)), Anthony Traboulsee(University of British Columbia), Nicole Mairon(Roche (Switzerland)), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Shibeshih Belachew(Roche (Switzerland)), Paulo Fontoura(Roche (Switzerland)), Kottil Rammohan(Martin College), Ludwig Kappos(University Hospital of Basel), Annette Sauter(Inserm), Hans‐Peter Hartung(The University of Sydney), Douglas L. Arnold(McGill University), Amit Bar‐Or(University of Pennsylvania), Gavin Giovannoni(University of British Columbia), Stephen L. Hauser(University of California, San Francisco), Giancarlo Comi(Vita-Salute San Raffaele University), Donna Masterman(University of British Columbia), Peter Chin(University of British Columbia), de Sèze(Hôpital d'Hautepierre)
Cited by 1,861
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k